Small Cap Feast

Small Cap Feast – 21 March 2019

Set Menu AIM:

Total number of AIM Companies (Incl Susp): 905

Total number of AIM Companies trading: 835*
* As at 11 March 2019

Set Menu NEX Growth:

Total number of NEX Growth Market Companies (Incl Susp): 89*

Total number of NEX Growth Market Companies trading: 87*
* As at 11 March 2019

Set Menu Standard List:

Total number of Standard List Companies (Incl Susp): 161*

Total number of Standard List Companies trading: 142*
* As at 11 March 2019

Dish of the Day:

Diaceutics DXRX.L, a data analytics and implementation services company which services the global pharmaceutical industry has joined AIM. Mkt Cap c. £53m  Raising £17m at 76p. FYDec18E rev £10.4m, PBT £0.9m.

Off the Menu:

No Leavers Today

Dish of the Day:

No Joiners Today

Off the Menu:

No Leavers Today

What’s Cooking in the IPO Kitchen?

Main Market (Premium)

US Solar Fund, a newly-established investment company focused on investing in solar power assets mainly in the US, looking to raise $250m at $1. Expected 16 April.

AIM

Network International Holdings—Pleading enabler of digital commerce across the Middle East and Africa  region, operating across over 50 highly underpenetrated payment markets that contain a total population of 1.5 bn. 2018 rev $298m, underlying EBITDA $152m.  Due April. No new funds to be raised. Secondary sell down. Targeting 25% of at least 25%.

Techniplas –global  producer and support services company providing highly engineered and technically complex components, making the supply chain to original equipment manufacturers more efficient.  FYDec17 rev $515m.

Breakfast Buffet

Base Resources (BSE.L) 14.50p £166.24m

Toliara Project PFS confirms status as a world-class mineral sands development.

  • Post-tax / pre-debt (real) NPV @ 10% discount rate of US$671m, measured at FID
  • Revenue to cost of sales ratio of 3.06
  • Stage 1 capex cost of US$439m – to establish a 13Mtpa mining processing operation
  • Stage 2 capex cost of US$67m – increases operation to 19Mtpa
  • Mineral Resources forming basis of PFS comprise of 588Mt @ 6.6% Heavy Mineral, from existing Measured & Indicated resources, for an initial LOM of 33 years
  • Mineral Separation Plant recoveries of 93.9% ilmenite, 79.0% zircon and 73.7% rutile

 

LPA Group (LPA.L) 113.50p £13.05m

AGM Statement .  “In my commentary published in January, I reported that the current year had started quietly, with delays to some major rail projects including Crossrail, with demand expected to pick up substantially as the year progresses.

As expected, the results for the first half will be affected by these delays. However, we now have delivery schedules for the delayed programmes and have won new contracts, which, as and when delivery dates are confirmed, should make the work load for the second half and the medium term potentially very pleasing. 

Order intake for the first five months of the financial year is at record levels.”

 

Strix Group (KETL.L) 157.20p £317.30m

FY Dec18 results from the   global leader in the design, manufacture and supply of kettle safety controls and other complementary water temperature management components.

Solid performance during 2018 including a 7.9% growth in sales volumes and 2.7% in net sales, rising to 4.5% on a constant currency basis, in line with expectations. Rev £93.8m. PBT £29.2m + 3.2%.

Careful cost management has allowed a gross profit margin of 41.5% (2017: 40.7%).

Net debt reduced to £27.5m, a 40.1% reduction since December 2017 (£45.9m
Proposed final dividend of 4.7p, with total dividends of 7.0p for the full year.

For 2019 recent acquisition of Halo Source assets and hedging of commodities set a solid platform for further delivery.

 

Sopheon (SPE.L) 1,002.50p £116.42m

FYDec18 results from the  international provider of software, expertise, and best practices for Enterprise Innovation Performance. Rev: $33.9m          (2017: $28.5m)
EBITDA: 8.9m (2017: 8.0m)
PBT:  $6.4m  (2017: $5.1m)  Cash:   $16.7m .  18 new customer wins (13 in the prior year). Full year 2019 revenue visibility of $20.6m (2017: $19.3m).

Mentioned in 22 research reports from leading industry voices such as Gartner and Forrester Research. Vision extended from innovation to helping major enterprises achieve their strategic goals, dramatically expanding horizons and potential.

Dividend proposed of 3.25p per share (2017: 2.5p).

“Strategically, now is the time to accelerate investment and solidify our leadership position.  Once again, we have ambitious plans, many of which depend on bringing in the right people in the coming year “.

 

Inspired Energy (INSE.L) 17.38p £123.16m

The “UK energy procurement consultant to UK and Irish corporates is delighted to feature in the 2018 UK Parliamentary Review, a series of independent publications, which aim to share best practice among policy makers and business leaders.”

As one of the UK’s largest energy advisers, Inspired Energy works with private and public sector organisations to reduce their energy costs and usage. CEO Mark Dickinson tells the Parliamentary Review how it supports 2,000 business in managing their energy costs, allowing them to focus on running a successful business.

The article outlines some of the surprising statistics that energy buying can impact on your business and highlights some key areas to focus on, which enabled Inspired Energy to deliver over £100m worth of historical revenue recovery to its clients over the past 18 months. 

 

Frontier IP (FIPP.L) 84.00p £34.53m

The “specialist in commercialising university intellectual property, is pleased to note today’s statement from portfolio company Exscientia , a world leader in artificial intelligence drug discovery, announcing a three-year partnership with global biopharma company Celgene Corporation.

The collaboration to accelerate drug discovery in oncology and autoimmunity includes an initial US$25m upfront payment to Exscientia. The Company is also eligible to receive substantial milestones based on the clinical, regulatory and commercial success of the programme, and is due to receive tiered royalties on net sales of any product”.

 

Synectics (SNX.L) 210.00p £36.48m

The specialist in the design, integration, control and management of advanced surveillance technology and networked security systems, announces that it has secured a contract in the oil & gas sector.

The oil & gas market has been very difficult for the last few years and has been characterised by mostly small-value contracts for necessary additions and expansions to existing sites.

This contract, which is expected to be worth around £1m during its life, is the largest new oil & gas order received by the Company for a number of years and is due to be delivered substantially in this financial year.

 

Kibo Energy (KIBO.L) 0.75p £5.56m

The multi-asset energy company, is pleased to provide an update on the Benga Power Plant Project in Mozambique. Further to the RNS published on January 30, 2019.

Highlights

Definitive Feasibility Study (‘DFS’) completed ahead of schedule and final review in progress

Coal Purchase Agreements (‘CPA’) with coal producers in advanced stage and progressing well

Meeting with EDM (Mozambique’s publicly owned electricity company) – planned for April 2019 to present final DFS and engage in further Power Purchase Agreement (‘PPA’) negotiations under the terms of existing MOU (See RNS of 12 December 2019)

PPA discussions with potential private off-takers in advanced stage and progressing well

Assessing integration of renewable technologies at the project

 

Verona Pharma (VRP.L) 57.50p £60.56m

The clinical stage biopharmaceutical company focused on developing and commercialising innovative therapies for respiratory diseases, announces that Dr. Martin Edwards will join the board as a Non-Executive Director. Dr. Edwards has over three decades of experience in the pharmaceutical and venture capital industries. He is currently Senior Partner of Novo Holdings, where he has held various positions since 2003. Novo Holdings has a shareholding of 11.76% in VRP.

 

Alba Minerals (ALBA.L) 0.23p £7.13m

Assay Results at Thule Black Sands, Greenland,  confirm a weighted average Total Heavy Mineral content of 45.4%

All samples taken were ilmenite-bearing, confirming a combined mineralised strike length of approximately 10 km. “”These results, achieved in our first full field season at TBS, give us great confidence as we move forward with our plans this year.  Further testwork and independent resource estimation work are being undertaken, and we will announce the results of those further analyses as and when they become available.”

 

Head Chef:

Derren Nathan
0203 764 2344
derren.nathan@hybridan.com

*A corporate client of Hybridan LLP

Disclaimer

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.